Lancet publishes retatrutide type 2 diabetes trial with 1.9% HbA1c drop
Lilly's triple agonist cut weight 11.5% to 15.3% over 40 weeks in the diabetes trial, with phase 3 obesity data reported up to about 29% weight loss.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 5 01:13 ETSource: mamabella.uk
The wire
- 01The Lancet published Eli Lilly's retatrutide type 2 diabetes trial, reporting HbA1c reductions of 1.7% to 1.9% and weight loss of 11.5% to 15.3% at 40 weeks; obesity phase 3 results reported up to roughly 29%.
- 02Retatrutide targets GLP-1, GIP and glucagon receptors in one peptide, and prescribers are already fielding patient questions about product sold online under its name.
- 03It is not approved anywhere and has no UK date or price; reported side effects include nausea, diarrhoea, vomiting and altered skin sensation, and the contribution of added energy expenditure remains unsettled.
From the source
Read at mamabella.ukWhat is retatrutide? How the 'GLP-3' weight-loss jab works, what the trials show and when you could get it
Here’s how the experimental triple-action jab nicknamed ‘GLP-3’ works, how it compares with Wegovy and Mounjaro, what the trials show, the side effects reported so far and when it could reach the UK
